Filtered By:
Drug: Aspirin
Procedure: Coronary Artery Bypass Graft
This page shows you your search results in order of date.
Order by Relevance | Date
Total 95 results found since Jan 2013.
Investigation of Combined Carotid Endarterectomy and Coronary Artery Bypass Graft Surgery Outcomes and Adverse Event Risk Factors in the Vascular Quality Initiative
CONCLUSIONS: Combined CEA and CABG provides excellent long-term mortality prevention in patients with co-existing severe coronary and carotid atherosclerosis. Simultaneous CEA and CABG provides equivalent stroke prevention and long-term survival to both a cohort of patients undergoing coronary revascularization within 5 years of CEA and patients undergoing isolated CEA or CABG in the literature. The two most impactful modifiable risk factors towards long-term stroke and mortality prevention for patients undergoing simultaneous CEA-CABG are patch placement at CEA site and adherence to statin medication therapy.PMID:37303074...
Source: Atherosclerosis - June 11, 2023 Category: Cardiology Authors: Ashley Penton Jonathan Lin Grant Kolde Matthew DeJong Matthew Blecha Source Type: research
Safety outcomes of anti-platelet therapy post coronary artery bypass graft surgery: A systematic review and network meta-analysis of randomized control trials
CONCLUSION: No significant difference was found between monotherapy or dual-antiplatelet therapy for the major bleeding risk safety outcome, however DAPT was found to have a significantly higher rate of minor bleeding complications post-CABG. DAPT should be considered as the antiplatelet modality of choice post-CABG.PMID:36803180 | DOI:10.1177/02676591231159513
Source: Perfusion - February 21, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Syed U Hasan Alina Pervez Arshad A Shah Syed DA Shah Muhammad Aslam Anosha Arshad Amna S Rajput M Mujeeb Zubair Source Type: research
Rivaroxaban Monotherapy is Preferable to Combination Therapy with Antiplatelets with Regards to Total Cardiovascular and Bleeding Events in Patients with AF and Stable CAD
In this study conducted across 294 centers, 2,215 patients were randomly assigned to rivaroxaban monotherapy, or therapy with rivaroxaban in combination with aspirin or a P2Y12 inhibitor. All patients were diagnosed with AF with a CHADS2 score greater than one, as well as confirmed CAD without percutaneous coronary intervention (PCI) or coronary artery bypass grafting within 12 months. Primary endpoints were the total number of first and subsequent bleeding and thrombotic events over a 24-month follow-up period. Thrombotic events included ischemic stroke, systemic embolism, myocardial infarction, and unstable angina requir...
Source: The Hospitalist - January 3, 2023 Category: Hospital Management Authors: Ronda Whitaker Tags: CAD & Atherosclerosis Cardiology In the Literature Source Type: research
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study
CONCLUSIONS: In high-risk patients with prior CABG, ticagrelor monotherapy reduced bleeding without compromising ischaemic outcomes compared with ticagrelor plus aspirin.PMID:35979636 | DOI:10.4244/EIJ-D-22-00319
Source: EuroIntervention - August 18, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Gennaro Sardella Frans J Beerkens George Dangas Davide Cao Usman Baber Samantha Sartori David J Cohen Carlo Briguori Robert Gil Johny Nicolas Zhongjie Zhang Dariusz Dudek Vijay Kunadian Ran Kornowski Giora Weisz Bimmer Claessen Steven O Marx Javier Escane Source Type: research
Ticagrelor: clinical development and future potential
Rev Cardiovasc Med. 2021 Jun 30;22(2):373-394. doi: 10.31083/j.rcm2202044.ABSTRACTPlatelets participate centrally in atherothrombosis, resulting in vessel occlusion and ischaemia. Consequently, optimisation of antiplatelet regimens has the potential to further reduce the residual burden of morbidity and mortality associated with atherosclerosis. Ticagrelor is a potent oral platelet P2Y12 receptor antagonist that (1) inhibits a central amplification pathway of platelet activation directly as well as via an active metabolite, (2) has a rapid onset and offset of antiplatelet action that remains consistent in the circulation d...
Source: Reviews in Cardiovascular Medicine - July 14, 2021 Category: Cardiology Authors: Nicholas C Sanderson William A E Parker Robert F Storey Source Type: research
